EUCTR2009-011309-18-FI进行中（未招募）不适用
A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care - PAUSE
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium0 个研究点目标入组 12,000 人开始时间: 2009年11月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •All patients who present spontaneously to the practice for an evaluation of premature ejaculation, or who have a diagnosis of premature ejaculation and are currently being treated will be considered as candidates for enrollment. There will be no protocol-specific selection criteria other than the guidance provided by the Summary of Product Characteristics for PRILIGY as it is intended that the participating health care provider will use the Summary of Product Characteristics for PRILIGY as a guide to identify appropriate patients for the study (Section 4.1 of the Summary of Product Characteristics, Therapeutic indication) and the types of patients who should use caution or avoid using PRILIGY (Section 4.3 of the Summary of Product Characteristics, Contraindications and Section 4.4 of the Summary of Product Characteristics, Special warnings and precautions for use).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •There will be no protocol-specific exclusion criteria other than the guidance provided by the Summary of Product Characteristics for PRILIGY as it is intended that the participating health care provider will use the Summary of Product Characteristics for PRILIGY as a guide to identify appropriate patients for the study (Section 4.1 of the Summary of Product Characteristics, Therapeutic indication) and the types of patients who should use caution or avoid using PRILIGY (Section 4.3 of the Summary of Product Characteristics, Contraindications and Section 4.4 of the Summary of Product Characteristics, Special warnings and precautions for use).
研究者
相似试验
尚未招募
不适用
18-Fluoride (18F) labelled Sodium Fluoride (NaF)) Positron Emission Tomography (PET)/Computer Tomography (CT); the impact on pre-operative staging of intermediate and high risk prostate cancerCancer - ProstateProstate CancerACTRN12614000877684Dr. Simon Harley20
尚未招募
不适用
Analysis of the profile of males with hypogonadism in the regional setting of North Queensland.HypogonadismMetabolic and Endocrine - Other metabolic disordersPublic Health - EpidemiologyACTRN12614000993695Apoorva Saboo200
招募中
不适用
A prospective cohort study of individuals with primary human imune defiecncy virus (HIV) infection to determine immunological and virological factors related to disease progressioACTRN12609000438257niversity of New South Wales20
已完成
不适用
A prospective observational study of patients with advanced cancer for the evaluation of checkpoint inhibitor-associated cardiovascular immune-related adverse eventsAdvanced non-small-cell lung cancer and advanced gastric cancer which are indications for anti-cytotoxic T-lymphocyte-associated antigen-4, anti-programmed death-1, and anti-programmed death-ligand 1 antibodies.JPRN-UMIN000032729Frontline Immunotherapy Team, Sendai Kousei Hospital129
招募中
不适用
A prospective observational study of patients with ankle sprain and instability in Korean Medicine clinics and hospitalKCT0004016Gachon University200